Clinical trials: sponsored by Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients
SP2086 is a novel inhibitor of Dipeptide base peptidase 4, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia.
- Trial name
- NCT02822534
- Testing
- SP2086
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
The Metabolite Identification and Material Balance Study of SP2086
The purpose of the study is to investigate the Metabolite identification and material balance of SP2086 in healthy adult volunteers.
- Trial name
- NCT02815748
- Testing
- SP2086
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
The DDI Study of SP2086 and Valsartan
The purpose of the study is to investigate the potential PK interaction between SP2086 and Valsartan after multiple oral doses treatment in healthy male volunteers.
- Trial name
- NCT02817217
- Testing
- SP2086, Valsartan
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
The DDI Study of SP2086 and Simvastatin
The purpose of the study is to investigate the potential interaction between multiple oral doses of SP2086 and a single oral dose of Simvastatin in healthy adult volunteers.
- Trial name
- NCT02817243
- Testing
- SP2086, Simvastatin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
The Drug-drug Interaction of SP2086 and Valsartan
The purpose of the study is to investigate the potential interaction between SP2086 and Valsartan after multiple oral doses treatment in healthy adult volunteers.
- Trial name
- NCT02815657
- Testing
- SP2086, Valsartan
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
The Drug-drug Interaction of SP2086 and Simvastatin
The purpose of the study is to investigate the potential interaction between SP2086 and Simvastatin after the multiple oral doses treatment in healthy adult volunteers.
- Trial name
- NCT02815722
- Testing
- SP2086, Simvastatin
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
The Drug -Drug Interaction of SP2086 and Glyburide
The purpose of the study is to investigate the potential interaction between SP2086 and Glyburide after the singe and multiple oral doses treatment in healthy adult volunteers respectively.
- Trial name
- NCT02815787
- Testing
- SP2086, Glyburide
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Renal Insufficiency
SP2086 Pharmacokinetic Study in Renal Insufficiency Patients
The purpose of the study is to investigate the SP2086 pharmacokinetic in Renal Insufficiency Patients.
- Trial name
- NCT02815774
- Testing
- SP2086
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
The Drug-drug Interaction of SP2086 and Metformin
This is an open single and self-control study,planning to recruit 24 cases of healthy male volunteers.In the study,subjects were given SP2086 and metformin,and collects blood samples before and after medcine.The purpose is to…
- Trial name
- NCT02813863
- Testing
- SP2086, Metformin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy
A Phase 1, Randomized, Placebo-controlled, Single & Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Healthy Chinese Volunteers
This is a randomized, placebo-controlled, single \& multiple dose escalation study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR0534.
- Trial name
- NCT02750553
- Testing
- SHR0534
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy
A PHASE I, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE DOSE ESCALATION STUDY TO INVESTIGATE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SHR0534 IN HEALTHY VOLUNTEERS
This is a randomized, placebo-controlled, single dose escalation study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR0534.
- Trial name
- NCT02749097
- Testing
- SHR0534
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Rheumatoid Arthritis
Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients
Condition: Rheumatoid Arthritis Intervention: Drug: SHR0302; Drug: SHR0302 placebo comparator Phase: Phase 1 Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator…
- Trial name
- NCT02665910
- Testing
- SHR0302
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Melanoma
A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients
SHR6390 is a small molecular,oral potent, selective CDK4/6 inhibitor. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in Chinese advanced melanoma patients by using a…
- Trial name
- NCT02671513
- Testing
- SHR6390
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Rheumatoid Arthritis
First-in-Human Single Ascending Dose of SHR0302
The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) oral doses of SHR0302 compared to placebo.
- Trial name
- NCT02423538
- Testing
- SHR0302
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
General Anesthesia
A Study Comparing Remimazolam Tosilate and Propofol for Intravenous General Anaesthesia in Operations
The purpose of this study is to find out the optimal dose for Remimazolam Tosilate as an intravenous general anaesthetic drug in operations and to determine its efficacy and safety profile comparing to propofol.
- Trial name
- NCT02406872
- Testing
- Remimazolam Tosilate, Propofol
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hypertriglyceridemia
Omega-3-Acid Ethyl Esters 90 Soft Capsules for Lowering Very High Triglycerides
The trial was a double-blind, randomized, parallel-group study comparing Omega-3-Acid Ethyl Esters 90 Soft Capsules and placebo.
- Trial name
- OMEELVHT (NCT02625870)
- Testing
- Omega-3-Acid Ethyl Esters 90 Soft Capsules, Corn Oil
- Volunteers
- 240 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Chronic Idiopathic Thrombocytopenic Purpura
Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
This study evaluates the safety and efficacy of 6 weeks dosing Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura Patients. All of the subjects in this study receive Hetrombopag.
- Trial name
- NCT02614846
- Testing
- Hetrombopag Olamine
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
The Drug-drug Interaction of SHR3824 and SP2086
The purpose of the study is to investigate the potential interaction between multiple oral doses of SHR3824 and multiple oral doses of SP2086 in healthy adult volunteers.
- Trial name
- NCT02500485
- Testing
- SHR3824, SP2086
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
The Drug-drug Interaction of SHR3824 and Metformin
The purpose of the study is to investigate the potential interaction between multiple oral doses of SHR3824 and a single oral dose of metformin in healthy adult volunteers.
- Trial name
- NCT02354027
- Testing
- SHR3824 metformin
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Knee Osteoarthritis
Pharmacokinetics of Imrecoxib in Subjects With Hepatic Insufficiency
This clinical research study will assess pharmacokinetics and the safety of Imrecoxib in patients with impaired hepatic function as compared to healthy volunteers.
- Trial name
- NCT02456688
- Testing
- Imrecoxib
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.